Jianmin Pharmaceutical Group Co

Jianmin Group has a national R&D platform focused on traditional Chinese medicine for pediatric and chronic conditions. Its postdoctoral research workstation and children’s drug research institute develop classical formulas, formulations, and patented technologies.

Jianmin Group supports access to affordable medicines, public outreach on traditional Chinese medicine, free children’s health consultations, rural revitalization through authentic medicinal herbs, and clean production. It also makes charitable donations during disasters.

Jianmin Group’s Video Center features promotional videos about factory tours from *Inside the Factory*, Longmu and children’s growth, smart manufacturing workshops, brand launch events, and traditional Chinese medicine’s intangible cultural heritage.

Jianmin is Jianmin Group’s core master brand and a China Well-Known Trademark. It focuses on adult chronic conditions and digestive, qi-and-blood, and throat health, with products including Bitong Capsules, Jianpi Shengxue Granules, and Jianmin Throat Tablets.

Jianmin Group’s official announcements section brings together all official disclosures, including annual equity distribution plans, quarterly reports, board resolutions, and earnings briefings, providing complete and accurate information.

Jianmin Group’s news section covers brand activities, product launches, strategic partnerships, industry conferences, children’s health education, and research awards. Its news includes Longmu brand IP, the Children’s Growth and Development Insights Report, and factory tours.

Jianmin Group holds China Time-Honored Brand and National Intangible Cultural Heritage credentials and has a National Enterprise Technology Center and an MIIT Green Factory.

Jianmin Pharmaceutical Group traces its roots to the 400-year-old Ye Kaitai pharmacy and focuses on pediatric Chinese patent medicines. Its integrated R&D, manufacturing, and sales chain supports three brands: Jianmin, Longmu, and Ye Kaitai.

Jianmin Group’s investor relations section provides stock information, company announcements, financial reports, investor returns, interactive Q&A, and investor education resources. It also lists an investor inquiry hotline and email.

Jianmin Group’s Investor Returns section publishes annual equity distribution plans, shareholder dividend policies, and action plans to improve efficiency and deliver returns, helping ensure investors’ right to information.

Jianmin Group carries forward Ye Kaitai’s intangible cultural heritage of traditional Chinese medicine preparation techniques and upholds its pharmaceutical precepts. It combines traditional Chinese medicine culture with modern management.

Jianmin Group provides information and services related to its medicines.

Jianmin Group regards talent as its greatest asset. It is committed to recognizing and making good use of people’s abilities, providing equal opportunities, and building a company-wide training system to develop well-rounded pharmaceutical professionals with diverse skills.

Founded in 1637 during the Ming dynasty, Jianmin Group focuses on medicines for children and women and signature Chinese medicine products. It is a national production base for pediatric medicines and owns the Jianmin and Longmu trademarks.